DrugPatentWatch Database Preview

Details for Patent: 6,713,446

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,713,446 protect, and when does it expire?

Patent 6,713,446 protects VELCADE and is included in one NDA.

Protection for VELCADE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in thirteen countries.

Summary for Patent: 6,713,446

Title:	Formulation of boronic acid compounds
Abstract:	The present invention provides stable compounds prepared from boronic acid and lyophilized compounds thereof of the formula (1): ##STR1## in which Z.sup.1 and Z.sup.2 are moieties derived from sugar. The invention also provides methods for preparing such compounds. Lyophilizing a mixture comprising a boronic acid compound and a moiety derived from sugar produces a stable composition that readily releases the boronic acid compound upon reconstitution in aqueous media.
Inventor(s):	Gupta; Shanker Lal (Rockville, MD)
Assignee:	The United States of America as represented by the Secretary of the Department of Health and Human Services (Washington, DC)
Application Number:	10/056,567
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,713,446
Patent Claim Types: see list of patent claims	Compound; Use; Composition;

Drugs Protected by US Patent 6,713,446

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Takeda Pharms Usa	VELCADE	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	021602-001	May 13, 2003		RX	Yes	Yes					Y

International Family Members for US Patent 6,713,446

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	501157
Australia	2002243646
Canada	2435124